Zelboraf (vemurafenib) — Medica
Hairy cell leukemia
Preferred products
- rituximab
- Gazyva (obinutuzumab)
Initial criteria
- age ≥ 18 years
- EITHER patient has tried at least one other systemic therapy (e.g., cladribine, Nipent [pentostatin], rituximab, Intron A [interferon alpha-2b]) OR patient is unable to tolerate purine analogs (e.g., active infection, frail patients) AND Zelboraf is used in combination with rituximab or Gazyva (obinutuzumab)
Approval duration
1 year